<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02419807</url>
  </required_header>
  <id_info>
    <org_study_id>CASE10114</org_study_id>
    <nct_id>NCT02419807</nct_id>
  </id_info>
  <brief_title>Comparison of Use of Indocyanine Green and 99mTc-labeled Radiotracer for Axillary Lymphatic Mapping in Patients With Breast Cancer</brief_title>
  <official_title>Comparison of Use of Indocyanine Green and 99mTc-labeled Radiotracer for Axillary Lymphatic Mapping in Patients With Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Case Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mitaka USA, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Case Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial will enroll up to 130 adult women with a confirmed diagnosis of clinical&#xD;
      stage 1 or 2 breast cancer who are undergoing breast cancer surgery with lumpectomy or&#xD;
      mastectomy and planned axillary sentinel node biopsy procedure. Participants will undergo&#xD;
      lymphatic mapping with technetium Tc-99m (99mTc) sulfur colloid in accordance with routine&#xD;
      clinical practice. Injections of 99mTc sulfur colloid will take place the afternoon prior to&#xD;
      planned next morning surgery or on the morning of surgery. Participants will undergo&#xD;
      lymphoscintigraphy in accordance with standard clinical practice.&#xD;
&#xD;
      Immediately prior to operation, after the induction of anesthesia in the operating room, up&#xD;
      to 1cc of 0.5% indocyanine green (ICG) solution will be injected subdermally close to the&#xD;
      tumor or into the subareolar region after disinfection of the breast skin. ICG movement will&#xD;
      be facilitated by manual massage and monitored with fluorescence imaging. ICG fluorescence&#xD;
      will be elicited and detected by Photodynamic Eye (PDE) camera. The lymphatic drainage, made&#xD;
      evident by the fluorescent dye, will be monitored in real time on a monitor. The fluorescence&#xD;
      will be followed towards the armpit region (axilla) and time for the fluorescence to reach&#xD;
      the axilla will be recorded. Following standard practice, an incision will be made in the&#xD;
      armpit region. Fluorescent lymph nodes (ICG positive) will be localized and removed and&#xD;
      analyzed by a pathologist. Node removal will continue until no residual fluorescence is&#xD;
      visible in the axilla. Removed nodes will be tested for radioactivity using a standard&#xD;
      gamma-detecting probe and the counts per minute will be recorded. Finally, the armpit region&#xD;
      will be inspected with the gamma probe to determine if there are any residual radioactive&#xD;
      nodes. Residual sentinel nodes (the first node to receive lymph from a tumor) will be&#xD;
      removed. For the purposes of this study, the sentinel status of a node will be defined as&#xD;
      being flagged as sentinel by either one or both of the ICG or 99mTc methods. The goal of the&#xD;
      project is to confirm that axillary lymphatic mapping with ICG leads to similar nodes being&#xD;
      labeled as sentinel as lymphatic mapping with 99mTc-labeled radiotracer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To confirm that axillary lymphatic mapping with indocyanine green solution (ICG) solution&#xD;
      leads to a similar number of nodes being labeled as sentinel as lymphatic mapping with&#xD;
      99mTc-labeled (technetium Tc-99m sulfur colloid) radiotracer.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Participants receive technetium Tc-99m sulfur colloid injection and undergo&#xD;
      lymphoscintigraphy according to clinical practice. Prior to surgery, participants also&#xD;
      receive indocyanine green solution subdermally close to the tumor or into subareolar region&#xD;
      of the breast skin. Participants then undergo axillary sentinel node biopsy and surgery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 17, 2015</start_date>
  <completion_date type="Actual">February 2019</completion_date>
  <primary_completion_date type="Actual">February 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Sentinel Lymph Nodes (SLNs) Flagged by the Two Methods</measure>
    <time_frame>Baseline</time_frame>
    <description>Let A be the number of Tc-positive and ICG-positive sentinel nodes (SNs) detected, B be the number of Tc-positive and ICG-negative SNs detected, and C be the number of Tc-negative and ICG-positive SNs detected. The total number (N) of SNs detected is therefore N = (A + B + C); the proportion of SNs detected by the Tc method (PTc) is (A + B)/N; and the proportion of SNs detected by the ICG method (PICG) is (A + C)/N. Differences in the proportions of SLNs flagged will be compared using a two-sided 95% confidence interval.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">102</enrollment>
  <condition>Stage I Breast Cancer</condition>
  <condition>Stage II Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Diagnostic (indocyanine green, 99mTc-labeled radiotracer)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive technetium Tc-99m sulfur colloid injection and undergo lymphoscintigraphy according to clinical practice. Prior to surgery, participants also receive indocyanine green solution subdermally close to the tumor or into subareolar region of the breast skin. Participants then undergo Axillary Lymph Node Biopsy and surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Indocyanine Green Solution</intervention_name>
    <description>Given subdermally</description>
    <arm_group_label>Diagnostic (indocyanine green, 99mTc-labeled radiotracer)</arm_group_label>
    <other_name>IC-GREEN</other_name>
    <other_name>ICG solution</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Technetium Tc-99m Sulfur Colloid</intervention_name>
    <description>Given via injection</description>
    <arm_group_label>Diagnostic (indocyanine green, 99mTc-labeled radiotracer)</arm_group_label>
    <other_name>Tc 99m Sulfur Colloid</other_name>
    <other_name>Tc-99m SC</other_name>
    <other_name>Technetium Tc 99m Sulfur Colloid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Lymphoscintigraphy</intervention_name>
    <description>This is a method used to check the lymph system for disease. A radioactive substance that flows through the lymph ducts and can be taken up by lymph nodes is injected into the body. A scanner or probe is used to follow the movement of this substance on a computer screen. Lymphoscintigraphy is used to find the sentinel lymph node (the first node to receive lymph from a tumor), which may be removed and checked for tumor cells. Lymphoscintigraphy is also used to diagnose certain diseases or conditions, such as lymphoma or lymphedema.</description>
    <arm_group_label>Diagnostic (indocyanine green, 99mTc-labeled radiotracer)</arm_group_label>
    <other_name>Undergo lymphoscintigraphy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Axillary Lymph Node Biopsy</intervention_name>
    <description>Undergo biopsy</description>
    <arm_group_label>Diagnostic (indocyanine green, 99mTc-labeled radiotracer)</arm_group_label>
    <other_name>Axillary Node Biopsy</other_name>
    <other_name>axillary sentinel lymph node biopsy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants with a confirmed diagnosis of clinical stage 1 or 2 breast cancer&#xD;
&#xD;
          -  Participants who are undergoing breast cancer surgery with lumpectomy or mastectomy&#xD;
&#xD;
          -  Participants with planned axillary sentinel node biopsy procedure&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants with cancer &gt; 3 cm&#xD;
&#xD;
          -  Participants with clinically positive nodes&#xD;
&#xD;
          -  Participants with prior surgery for breast cancer in the index breast&#xD;
&#xD;
          -  Participants who have had bilateral breast surgeries&#xD;
&#xD;
          -  Thyroid dysfunction&#xD;
&#xD;
          -  Hypersensitivity to iodine&#xD;
&#xD;
          -  Hepatic insufficiency&#xD;
&#xD;
          -  Renal insufficiency&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen Grobmyer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Case Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cleveland Clinic Taussig Cancer Instititute, Case Comprehensive Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>April 14, 2015</study_first_submitted>
  <study_first_submitted_qc>April 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 17, 2015</study_first_posted>
  <results_first_submitted>September 29, 2020</results_first_submitted>
  <results_first_submitted_qc>September 29, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">October 22, 2020</results_first_posted>
  <last_update_submitted>October 20, 2020</last_update_submitted>
  <last_update_submitted_qc>October 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Near Infrared Fluorescence Imaging</keyword>
  <keyword>Indocyanine Green</keyword>
  <keyword>axillary lymph node mapping</keyword>
  <keyword>Mastectomy, Segmental</keyword>
  <keyword>Sentinel Lymph Node Biopsy</keyword>
  <keyword>Lumpectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Technetium Tc 99m Sulfur Colloid</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 18, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/07/NCT02419807/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 13, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/07/NCT02419807/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Diagnostic (Indocyanine Green, 99mTc-labeled Radiotracer)</title>
          <description>Participants receive technetium Tc-99m sulfur colloid injection and undergo lymphoscintigraphy according to clinical practice. Prior to surgery, participants also receive indocyanine green solution subdermally close to the tumor or into subareolar region of the breast skin. Participants then undergo Axillary Lymph Node Biopsy and surgery.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="102"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="92"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Participants who enrolled on study</population>
      <group_list>
        <group group_id="B1">
          <title>Diagnostic (Indocyanine Green, 99mTc-labeled Radiotracer)</title>
          <description>Participants receive technetium Tc-99m sulfur colloid injection and undergo lymphoscintigraphy according to clinical practice. Prior to surgery, participants also receive indocyanine green solution subdermally close to the tumor or into subareolar region of the breast skin. Participants then undergo Axillary Lymph Node Biopsy and surgery.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="102"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="102"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="96"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="90"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Tc-positive and ICG-positive sentinel nodes (SNs)</title>
          <units>sentinel nodes</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="191"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Tc-positive and ICG-negative sentinel nodes (SNs)</title>
          <units>sentinel nodes</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Tc-negative and ICG-positive SNs</title>
          <units>sentinel nodes</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total sentinel lymph nodes (SLNs)</title>
          <units>sentinel nodes</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="235"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Sentinel Lymph Nodes (SLNs) Flagged by the Two Methods</title>
        <description>Let A be the number of Tc-positive and ICG-positive sentinel nodes (SNs) detected, B be the number of Tc-positive and ICG-negative SNs detected, and C be the number of Tc-negative and ICG-positive SNs detected. The total number (N) of SNs detected is therefore N = (A + B + C); the proportion of SNs detected by the Tc method (PTc) is (A + B)/N; and the proportion of SNs detected by the ICG method (PICG) is (A + C)/N. Differences in the proportions of SLNs flagged will be compared using a two-sided 95% confidence interval.</description>
        <time_frame>Baseline</time_frame>
        <population>Participants who completed study</population>
        <group_list>
          <group group_id="O1">
            <title>Diagnostic (Indocyanine Green, 99mTc-labeled Radiotracer)</title>
            <description>Participants receive technetium Tc-99m sulfur colloid injection and undergo lymphoscintigraphy according to clinical practice. Prior to surgery, participants also receive indocyanine green solution subdermally close to the tumor or into subareolar region of the breast skin. Participants then undergo Axillary Lymph Node Biopsy and surgery.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Sentinel Lymph Nodes (SLNs) Flagged by the Two Methods</title>
          <description>Let A be the number of Tc-positive and ICG-positive sentinel nodes (SNs) detected, B be the number of Tc-positive and ICG-negative SNs detected, and C be the number of Tc-negative and ICG-positive SNs detected. The total number (N) of SNs detected is therefore N = (A + B + C); the proportion of SNs detected by the Tc method (PTc) is (A + B)/N; and the proportion of SNs detected by the ICG method (PICG) is (A + C)/N. Differences in the proportions of SLNs flagged will be compared using a two-sided 95% confidence interval.</description>
          <population>Participants who completed study</population>
          <units>proportion of nodes</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Proportion of SNs (PTc) detected by Tc method</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Proportion of SNs (PICG) detected by ICG method</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Equivalence is defined as the difference in the proportions of nodes flagged between the Tc and ICG methods falling within an interval (-δ, +δ), where δ is taken to be 5%.</non_inferiority_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.036</ci_lower_limit>
            <ci_upper_limit>0.151</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Participants were monitored for adverse events for 30 days following their surgical operation</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Diagnostic (Indocyanine Green, 99mTc-labeled Radiotracer)</title>
          <description>Participants receive technetium Tc-99m sulfur colloid injection and undergo lymphoscintigraphy according to clinical practice. Prior to surgery, participants also receive indocyanine green solution subdermally close to the tumor or into subareolar region of the breast skin. Participants then undergo Axillary Lymph Node Biopsy and surgery.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Stephen Grobmyer</name_or_title>
      <organization>Cleveland Clinic, Case Comprehensive Cancer Center</organization>
      <phone>1-866-223-8100</phone>
      <email>TaussigResearch@ccf.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

